Core Viewpoint - Haohai Biology is expanding its business by acquiring a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membrane, despite Ruiji's ongoing financial losses and lack of performance guarantees in the transaction [1][3]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been struggling with losses of 11.77 million yuan last year and 11.29 million yuan in the first three quarters of this year [1][2]. - The transaction does not grant Haohai Biology control over Ruiji's existing team or decision-making on financial and operational matters, as the stake does not allow for consolidation in Haohai's financial reports [2]. Group 2: Financial Performance of Haohai Biology - Haohai Biology's core business has been under pressure, with a revenue decline of 7.12% and a net profit drop of 10.29% in the first half of this year compared to the previous year [1][5]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan last year, with growth rates slowing significantly [5]. - In the first three quarters of this year, Haohai's revenue was 1.899 billion yuan, down 8.47%, and net profit was 305 million yuan, down 10.63% [7]. Group 3: Market Context and Competition - The global amniotic membrane market is projected to grow from over 1.89 billion dollars last year to 3.97 billion dollars by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9]. - Analysts suggest that while the acquisition may provide strategic benefits, the ongoing losses and competitive landscape present significant challenges for Haohai Biology [9].

Core Viewpoint - Haohai Biology has acquired a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membranes, despite Ruiji's ongoing financial struggles and lack of performance guarantees in the transaction [1][4]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been facing financial difficulties with losses of 11.77 million yuan in 2024 and 11.29 million yuan in the first nine months of 2025 [1][3]. - The transaction does not include any performance commitments or earn-out arrangements, posing a risk of investment loss if Ruiji's performance declines further [4]. Group 2: Haohai Biology's Business Context - Haohai Biology, the first biopharmaceutical company listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board, has seen a decline in its core business, with revenue and net profit dropping by 7.12% and 10.29% respectively in the first half of 2025 [1][6]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan in 2024, but growth has stagnated, with significant declines in its medical aesthetics, ophthalmology, and orthopedics segments [6][7]. Group 3: Market Potential and Competition - The global amniotic membrane market is projected to grow from 1.89 billion USD in 2024 to 3.97 billion USD by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9].

Core Viewpoint - Haohai Biological Technology (06826.HK) announced a share purchase agreement to acquire approximately 19.8% of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. and an additional 2.4554% by a personal buyer, which will enhance its presence in the high-value medical device market for orthopedics and ophthalmology [1] Group 1 - The acquisition will be completed in three phases between 2025 and 2026, with total cash consideration of RMB 38,351,487.36 for Buyer I and RMB 4,755,979.05 for Buyer II [1] - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and injury repair, and tear duct obstruction support [1] - By investing in the target company, the group aims to enter the high-value biological amniotic membrane market, complementing its existing product portfolio and expanding its business layout in orthopedics and ophthalmology [1] Group 2 - The amniotic materials held by the target company possess human-derived biological characteristics, providing the group with critical technology and material foundations in regenerative medicine and tissue engineering [1] - This investment is expected to drive subsequent product innovation and technological upgrades within the group [1]

Group 1 - The core point of the article is that Haohai Biological Technology (06826.HK) has entered into a share purchase agreement to acquire approximately 19.8% of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. and an additional 2.4554% by a personal buyer, with the total cash consideration amounting to RMB 38,351,487.36 for the first buyer and RMB 4,755,979.05 for the second buyer [1] Group 2 - The share transfer will be completed in three phases between 2025 and 2026 [1] - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and lesion repair, and tear duct obstruction support [1] - By investing in the target company and obtaining distribution rights for its products in China, the group aims to enter the high-value medical device market of biological amniotic membranes, enhancing its existing product portfolio and expanding its business in orthopedics and ophthalmology [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the group with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive future product innovation and technological upgrades [1]

Core Viewpoint - Haohai Biological Technology (06826) announced plans to acquire approximately 19.8% and 2.4554% stakes in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for approximately 38.35 million yuan and 4.756 million yuan respectively, aiming to enter the high-value medical device market in China [1] Group 1 - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and injury lesion repair, and tear duct obstruction [1] - By investing in the target company and obtaining distribution rights for its products in China, the company aims to enhance its product portfolio and expand its business layout in the orthopedic and ophthalmic fields [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the company with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive subsequent product innovation and technological upgrades [1]

Core Viewpoint - Haohai Biological Technology (06826) plans to acquire approximately 19.8% and 2.4554% equity stakes in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for approximately 38.35 million yuan and 4.756 million yuan respectively, aiming to enter the high-value medical device market of biological amniotic membranes and expand its business in orthopedics and ophthalmology [1] Group 1 - The target company's products are primarily used in orthopedics and ophthalmology for tendon injury repair, ocular surface burns, wound and lesion repair, and support after lacrimal duct obstruction [1] - By investing in the target company and obtaining distribution rights for its products in China, the company will enhance its existing product portfolio and expand its business layout in the orthopedic and ophthalmic fields [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the company with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive subsequent product innovation and technological upgrades [1]